Predicting IBD Treatment Outcomes With Gut Microbiome Analysis (NCT06453720)
Optimizing Patient Treatment Involving Microbiome Integration for Specialized Therapeutics
๐ฉบ Plain-English Summary (8th-Grade Level)
The goal of this prospective observational study is to determine if specific microbiome signatures can predict therapeutic responses in adult patients with Crohn's disease (CD), a form of inflammatory bowel disease (IBD), living in British Columbia, Canada. The main questions this study seeks to answer are: 1. Can microbiome signatures across different sample types (fecal, intestinal washings, and intestinal epithelial biopsies) predict response to therapy in CD? 2. How do microbiome profiles differ between active and quiescent CD and non-IBD controls? Researchers will compare microbiome signatures in patients with active and inactive CD as well as non-IBD controls to see if there are any microbial signatures that predict response to therapy. Participants will: 1. Provide fecal and blood samples. 2. Undergo intestinal washings and intestinal epithelial biopsy specimens taken during routine colonoscopy. 3. Participate in a longitudinal follow-up over 12 months to monitor clinical, biochemical, and endoscopic responses to therapy.
Who can join: Review the eligibility criteria below.
Location: GI Research Institute โ Vancouver, British Columbia
Age range: 19 Years to 80 Years
๐งช Interventions in This Study
- Colonoscopy (PROCEDURE)
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- GI Research Institute โ Vancouver, British Columbia
๐ Contact the Study Coordinator
Phone: (604) 441-4992
Email: flemarie@ibdcentrebc.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Inflammatory Bowel Diseases
- Implementing a Multimodal RCT Intervention to Improve the Transition of Patients With Crohn's Disease From Pediatric to Adult Care โ Vancouver, British Columbia
- PRecisiOn Microbiome Directed ExtensiOn of Anti-TNFฮฑ Crohn's Disease ThErapy in Children: The PROMOTE Trial โ Ottawa, Ontario
- A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy โ Baltimore, Maryland
- Outpatient VR (Virtual Reality)-Brain-gut Behavioral Therapies (BGBT) in Inflammatory Bowel Disease (IBD) โ Ann Arbor, Michigan
- A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease โ Lancaster, California
- A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC โ Sun City, Arizona
Explore by condition: All Inflammatory Bowel Diseases clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.